Lymphogranuloma venereum future or investigational therapies
|
Lymphogranuloma venereum Microchapters |
|
Differentiating Lymphogranuloma venereum from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphogranuloma venereum future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Lymphogranuloma venereum future or investigational therapies |
|
FDA on Lymphogranuloma venereum future or investigational therapies |
|
CDC on Lymphogranuloma venereum future or investigational therapies |
|
Lymphogranuloma venereum future or investigational therapies in the news |
|
Blogs on Lymphogranuloma venereum future or investigational therapies |
|
Risk calculators and risk factors for Lymphogranuloma venereum future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Further recommendations
As with all STD's sex partners of patients who have LGV should be examined and tested for urethral or cervical chlamydial infection. After a positive culture for chlamydia, clinical suspicion should be confirmed with testing to distinguish serotype. Antibiotic treatment should be started if they had sexual contact with the patient during the 30 days preceding onset of symptoms in the patient. Patients with a sexually transmitted disease need to be tested for other STD's. Antibiotics are not without risks and prophylaxtic broad antibiotic coverage is not recommended.